sábado, 14 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 20, 2026

Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?

View original at finance.yahoo.com
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Achieved approximately $1 billion in savings in 2025

    80% confidence

  • Operating expenses expected to decline in 2026, supporting margin expansion

    80% confidence

  • Zacks Consensus Estimate for BMY's 2026 EPS suggests increase of 0.33%

    80% confidence

  • Zacks Consensus Estimate for BMY's 2026 sales implies year-over-year decrease of 2.32%

    80% confidence

  • Expects headwind of approximately $2.5 billion from generic competition in 2026

    80% confidence

  • Zacks Consensus Estimate for MRK's 2026 sales implies year-over-year increase of 2.59%

    80% confidence

  • Keytruda targets peak sales of $35 billion by 2028

    80% confidence

  • Phase III pipeline has almost tripled since 2021

    80% confidence

  • Keytruda will lose patient exclusivity in 2028

    80% confidence

  • Annual revenue guidance of $46.0-$47.5 billion for 2026

    80% confidence

  • BMY's relatively attractive valuation and more favorable 2026 outlook position it as the more compelling investment choice versus MRK at present

    80% confidence

  • Zacks Consensus Estimate for MRK's 2026 EPS suggests decline of 38.75%

    80% confidence

  • Legacy Portfolio sales expected to decline 12-16% in 2026

    80% confidence

  • Expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s

    80% confidence

  • Positioned to launch around 20 drugs over the next few years, with many having blockbuster potential

    80% confidence

  • Targeting $2 billion in annualized cost savings by the end of 2027

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? — Source | Via News | es.VIA.NEWS